RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline

Roche (RHHBY) announced the acquisition of 89bio (ETNB) for an estimated $3.5 billion, including contingent value rights (CVRs), aiming to bolster its cardiovascular, renal, and metabolic diseases (CVRM) portfolio. The deal, valued at $14.50 per share upfront plus up to $6.00 per share in CVRs tied to pegozafermin's commercial milestones, represents a 52% premium and strategically adds a late-stage MASH asset with significant revenue potential in the growing obesity-related disease market and synergy opportunities. Expected to close in Q4 2025, the announcement led to a pre-market surge in ETNB stock.

Analysis

Roche is executing a strategic acquisition of 89bio to bolster its cardiovascular, renal, and metabolic (CVRM) pipeline, paying a significant 52% premium over the 60-day volume-weighted average price for the clinical-stage company. The deal is structured with $2.4 billion in upfront cash at $14.50 per share and an additional potential $1.0 billion through non-tradeable contingent value rights (CVRs), bringing the total consideration to $3.5 billion. The core asset acquired is pegozafermin, a late-stage (Phase III) candidate for metabolic dysfunction-associated steatohepatitis (MASH), a prevalent comorbidity of obesity. This move not only adds a promising, de-risked asset with a distinct mechanism of action but also creates potential synergies with Roche's existing incretin portfolio. The CVRs are tied to ambitious, long-term commercial milestones, including achieving $4.0 billion in annual sales by 2035, which effectively de-risks a portion of the investment for Roche by linking payment to performance. This acquisition aligns with Roche's strong year-to-date stock performance of 20.4%, which has significantly outpaced the industry's 2.5% growth, and positions the company to capitalize on the highly lucrative obesity-related disease market.

Key Decisions for Investors

• For 89bio shareholders, the immediate 52% premium offers a significant upfront cash return, but realizing the full valuation is contingent on long-term commercial milestones tied to the CVRs, which carry inherent risk and a lengthy time horizon extending to 2035.
• Roche investors should view this as a strategic long-term investment to bolster its CVRM pipeline with a late-stage asset in the lucrative MASH market, noting the CVR structure prudently ties a significant portion of the acquisition cost to future commercial success.
• This acquisition signals strong M&A appetite for de-risked assets in the metabolic disease space, suggesting investors should re-evaluate valuations of other clinical-stage biotech firms with promising candidates in MASH and related indications.